Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease.
S NeumannJ TaylorA BamfordC MetcalfeD M GauntA WhoneD SteedsS R EmmettW HollingworthY Ben-ShlomoEmily J HendersonPublished in: BMC neurology (2021)
41639809 (registered 16/04/2019). ClinicalTrials.gov Identifier: NCT04226248 PROTOCOL AT TIME OF PUBLICATION: Version 7.0, 20th January 2021.